2013～2017年我院核苷类抗肝炎药物门诊使用分析  

Analysis of the Utilization of Nucleosides Anti-hepatitis Drug in Outpatient Department in Our Hospital from 2013 to 2017

作　　者：沈洁[1] 曹辉 殷萍萍 Shen Jie;Cao Hui;Yin Pingping(Department of Pharmacy,The Second Hospital of Nanjing,Nanjing University of Traditional Chinese Medicine,Nanjing 210003,China)

机构地区：[1]南京中医药大学附属南京医院(南京市第二医院),南京210003

出　　处：《药物流行病学杂志》2018年第10期681-685,共5页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:了解我院2013～2017年核苷类抗肝炎药物门诊应用情况,分析核苷类抗肝炎药物应用特点和趋势。方法:汇总我院2013～2017年5种核苷类抗肝炎药物的门诊使用数据,对用药种类、销售金额、用药频度(DDDs)及限定日费用(DDC)等进行统计分析。结果:2013～2017年,5种核苷类抗肝炎药物的消耗量逐渐递增,其中富马酸替诺福韦二吡呋酯增幅最高,增加了21. 75倍; 5种核苷类抗肝炎药物中,恩替卡韦的销售金额及其构成比和DDDs均居榜首,销售金额逐年增长,增加了0. 75倍,5年内富马酸替诺福韦二吡呋酯的销售金额和DDDs增幅最大,分别增加了6. 29倍和21. 75倍; 5种核苷类药物的DDC逐渐降低,富马酸替诺福韦二吡呋酯的DDC降低幅度最大,降低了68%。结论:核苷类抗肝炎药物的使用正逐步规范化,该类药物仍是目前治疗病毒性肝炎的主要药物,其中替诺福韦将在临床中发挥更大的作用。Objective： To investigate the utilization condition of nucleosides anti-hepatitis drug in our hospital from 2013 to 2017, the characteristics and tendency so as to provide references for the rational use and scientific management of nueleosides anti-hepatitis drug. Methods：The consumption data about nucleosides anti-hepatitis drug in our hospital during 2013-2017 were collected for analysis of categories, consumption sum, DDDs and DDC etc. Results：From 2013 to 2017, the consumption of five nucleosides anti-hepatitis drug increased year by year, with Tenofovir disoproxil fumarate having the highest increase of 21.75 times. In the 5 nucleoside anti-hepatitis drugs, consumption sum, constituent ratio and DDDs of Entecavir were all top of the list, the amount of sales increased year by year, an increase of 0.75 times. Tenofovir disoproxil fumarate had the biggest increase of consumption sum and DDDs in the five years, increased by 6.29-fold and 21.75- fold. DDC of the 5 nucleoside anti-hepatitis drugs gradually decreased, Tenofovir disoproxil fumarate had the biggest decrease of DDC with 68%. Conclusion：The utilization of nucleosides anti-hepatitis drug is getting more and more standard, and these drugs are still the main drug for treatment of viral hepatitis, and Tenofovir will play a greater role in clinical practice.

关 键 词：核苷类抗肝炎药物 替诺福韦 用药频度 限定日费用 排序比 

分 类 号：R978.7[医药卫生—药品]